<DOC>
	<DOCNO>NCT02328261</DOCNO>
	<brief_summary>This phase 2 study evaluate efficacy single-agent icotinib patient advance nasopharyngeal carcinoma .</brief_summary>
	<brief_title>A Phase II Study Icotinib Treating Patients With Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This phase 2 study aim evaluate efficacy single-agent icotinib patient pretreated , advance nasopharyngeal carcinoma . The primary endpoint disease control rate ( DCR ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Histologically confirm advanced NPC Patients must platinumresistant defined recurrence progression disease &lt; 6 month since previous treatment platinum base treatment regimen . Measurable disease per RECIST Adequate organ marrow function Capable understand comply protocol , write informed consent Prior treatment gefitinib , erlotinib , drug target EGFR Patients must receive investigational agent Other serious illness medical condition include unstable cardiac disease require treatment , history significant neurologic psychiatric disorder ( include psychotic disorder , dementia , seizure ) , active uncontrolled infection Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>